Quick Facts

• Condition Managed: Stage III colon cancer, advanced colorectal cancer.
• Therapeutic Role: Adjuvant treatment following primary tumor removal; treatment for advanced disease.
• Administration: Used as part of combination therapy, typically with fluorouracil and leucovorin.

---

Oxaliplatin is a chemotherapy agent used in the management of specific types of cancer. Its primary therapeutic applications are focused on colorectal carcinoma.

This medication is indicated for the adjuvant treatment of Stage III colon cancer in patients who have undergone complete surgical resection of the primary tumor. In this setting, the therapy is provided following surgery to help manage the disease process.

Oxaliplatin is also used for the treatment of advanced colorectal cancer. For this indication, the medicine is commonly administered as a component of a combination regimen with infusional fluorouracil and leucovorin, which may help to reduce the tumor burden and manage the progression of the disease. This agent is available by prescription only and should be administered under the guidance of a qualified healthcare provider.

Oxaliplatin is approved for use only in adults; its safety and effectiveness have not been established in the pediatric population. Older adults (age 65 and over) are generally eligible and do not require specific starting dose adjustments based on age alone.

Contraindicated Populations

Official regulatory documents state that Oxaliplatin must not be used in patients with:

• A known history of hypersensitivity reaction to oxaliplatin or other platinum-based drugs.
• A peripheral sensory neuropathy with functional impairment prior to the first course of treatment.
• Myelosuppression prior to therapy initiation (low baseline neutrophil and/or platelet counts).
• Severe renal impairment (creatinine clearance less than 30 mL/min) according to many international labels.
• Pregnancy and breastfeeding women.

Condition-Specific Limitations

Patients with mild to moderate renal impairment are generally eligible but require close monitoring. Use in severe renal impairment is restricted, though some U.S. labels permit a dose reduction for the initial cycle instead of absolute exclusion. Females and males of reproductive potential must be advised to use effective contraception during and for a specified period after receiving the final dose.

Interactions with other medicines and products

Official regulatory documentation for Oxaliplatin defines several crucial interaction constraints related to pharmacokinetics, pharmacodynamics, and administration procedures.

Pharmacokinetic and Metabolic Interactions

Regulatory assessments indicate that no P450-mediated drug-drug interactions are anticipated, as Oxaliplatin does not significantly inhibit or induce human cytochrome P450 isoenzymes. However, 5-Fluorouracil (5-FU) plasma concentrations may be increased by approximately 20% when co-administered with Oxaliplatin at the higher dose of 130 mg/m². The clearance of active platinum species may also be reduced by the co-administration of potentially nephrotoxic compounds.

Pharmacodynamic and Physical Incompatibilities

Interaction Type	Interacting Substance/Class	Official Constraint
Pharmacodynamic Risk	Products that prolong the QT interval	Avoid co-administration due to potential for additive effect.
Physical Incompatibility	Alkaline medications or media	Must not be mixed or co-administered through the same infusion line.
Physical Incompatibility	Components containing Aluminum	Must not be used during preparation or administration due to documented degradation.
Pharmacodynamic Risk	Oral anticoagulants	Co-administration has been associated with reports of hemorrhage and altered INR/Prothrombin Time.

These official statements structure the overall interaction profile, defining clear administration restrictions, highlighting specific pharmacokinetic alterations with common chemotherapy partners, and identifying pharmacodynamic risks.

Molecular Cross-Linking and DNA Synthesis Blockade

The primary mechanism of action involves the platinum-containing molecule forming strong, irreversible covalent bonds with the cell's DNA, specifically at the N7 position of guanine bases. This results in the formation of bulky platinum-DNA adducts, which physically block crucial enzymes like DNA and RNA polymerases. The resulting inhibition of replication and transcription is the molecular step that functionally inhibits cell division and genetic material duplication in affected cells.

---

Inducing Programmed Cell Death (Apoptosis)

The severe, irreparable damage to the DNA triggers the cell's intrinsic DNA Damage Response (DDR) pathway, which forces the cell to halt division at the G2/ M cell cycle checkpoint. When cellular repair systems fail to correct the damage, the arrested cell is irreversibly committed to apoptosis, a controlled process of self-destruction. This mechanism of regulated cellular elimination leads to the physiological consequence of a decrease in the number of rapidly proliferating cells.

---

Structural Evasion of DNA Repair Mechanisms

A key differentiator is the trans-1,2-diaminocyclohexane (DACH) ligand, which causes the DNA adducts to adopt a unique conformation that is poorly recognized by components of the DNA Mismatch Repair (MMR) system. This evasion of repair pathways ensures that the cytotoxic damage persists, as the lesion is poorly recognized by the MMR system. This structural property is also mechanistically linked to pathways that modulate the sensitivity of the cell to co-administered agents, resulting in combined cellular disruption.

Official Administration Guidelines for Оксалиплатин

Оксалиплатин must be administered exclusively by a healthcare professional in a specialized setting, following strict protocols outlined in prescribing information.

Route and Frequency

The medication is delivered via Intravenous (IV) infusion only. The standard regimen involves a single infusion administered on Day 1 of a 14-day cycle (every two weeks) as part of a combination regimen with fluorouracil and leucovorin.

Standard Dosing and Duration

Usage Setting	Standard Dose	Treatment Duration	Dose Adjustment Example
Adjuvant Treatment	85 mg/m² Body Surface Area (BSA)	Up to 12 cycles (6 months)	Reduced to 75 mg/m² for persistent neurosensory events.
Advanced Disease	85 mg/m² BSA	Until disease progression	Reduced to 65 mg/m² for persistent neurosensory events.

Key Administration Instructions

• Infusion Time: The dose is administered over a set time of 120 minutes (2 hours). This infusion time may be prolonged, up to 6 hours, under specific conditions.
• Preparation: The concentrate must be diluted solely with 5% Dextrose Injection (D5W). It must not be prepared or diluted with sodium chloride or other chloride-containing solutions.
• Sequence: The infusion of Оксалиплатин must always precede the administration of 5-fluorouracil.
• Renal Impairment: For patients with severe renal impairment (Creatinine Clearance <30 mL/min), the official initial recommended dose is lower at 65 mg/m².

Оксалиплатин: Recent Clinical Evidence

Clinical research has extensively evaluated Oxaliplatin in combination with fluoropyrimidine-based regimens for treating colorectal cancer (CRC). It is a standard component of both adjuvant (post-surgery) and metastatic treatment protocols.

Key Research Findings in Colorectal Cancer

Adjuvant therapy studies in Stage III colon cancer patients have demonstrated that regimens including oxaliplatin, such as FOLFOX or CAPOX, were associated with an improved rate of disease-free survival and, in some trials, overall survival, compared to regimens without it. The benefit may be more pronounced in patients under 70 years of age.

For metastatic colorectal cancer (mCRC), oxaliplatin-based regimens are widely used as first-line therapy, with studies tracking high response rates and prolonged progression-free survival compared to monotherapy or certain other combination treatments. The drug's efficacy profile may diminish with retreatment in late-line settings or in patients who have received extensive prior therapies.

Expanding Role in Other Cancers

Oxaliplatin's role is also explored in other gastrointestinal malignancies, often in combination with other agents (e.g., gemcitabine or fluorouracil), for:

• Gastric and Gastroesophageal Junction Cancers: Studies suggest a role, with some trials demonstrating non-inferiority to cisplatin-based regimens.
• Pancreatic Cancer: It is included in combinations, such as FOLFIRINOX, studied for both locally advanced and metastatic disease, with research tracking outcomes like resectability and survival measures.

Safety and Subgroup Analysis

Recent real-world and retrospective studies continue to investigate patient subgroups that may benefit most from oxaliplatin, considering factors like age and tumor characteristics (e.g., intrinsic subtypes). Long-term safety data remains crucial, especially concerning oxaliplatin-induced peripheral neuropathy, which is a key limiting factor in extended treatment.

Common questions about Оксалиплатин (FAQ)

---

Q: Do all patients experience hair loss when taking Оксалиплатин?

Hair loss, also known as alopecia, is a side effect documented in official drug information for Оксалиплатин. However, not all patients experience this effect. It is not listed among the most frequent adverse reactions, such as nausea or nerve changes.

---

Q: Are there any known food or drink items that interact with Оксалиплатин?

Official regulatory documents focus on drug-to-drug interactions and physical incompatibilities with the infusion solution. Regulatory preparation guidelines include a note regarding the physical incompatibility of the medicine with alkaline substances. There are no specific food or drink items listed as official contraindications that interact directly with the drug itself.

---

Q: What are the rules regarding driving while undergoing treatment with Оксалиплатин?

The official safety information notes that side effects may impact a person's ability to perform activities requiring alertness, such as driving or operating heavy machinery. This warning is based on the documented possibility of side effects like dizziness, nausea, vomiting, or changes in vision, which could affect a person's ability to drive safely.

---

Q: How long does the effect of a single Оксалиплатин treatment last?

According to regulatory pharmacokinetic studies, the drug's active component is eventually cleared from the body, but platinum-containing molecules remain present in the blood for a prolonged period. The time it takes for half of the substance to clear (terminal half-life) can be approximately 16 days.

---

Q: Does Оксалиплатин interact with common over-the-counter pain relievers?

Regulatory guidance notes that the drug is cleared by the kidneys, and caution is needed with nephrotoxic products, which are those that may cause kidney damage, such as certain non-prescription pain relievers. Also, since elevated liver enzymes are a common side effect, medicines that affect the liver may also require closer monitoring.

---

Q: Are there restrictions on getting vaccinated while receiving Оксалиплатин?

The official safety information notes that Оксалиплатин can cause severe myelosuppression, a condition that lowers blood cell counts and affects the immune system. Because of this effect on the body's immune defenses, regulatory guidance often recommends careful consideration regarding the use of vaccines, particularly those that contain live viruses.

---

Q: What are the signs of an allergic reaction to Оксалиплатин?

Official regulatory documents highlight the risk of serious allergic reactions, including anaphylaxis. Common signs can include a rash, hives, or itching, along with more severe symptoms. These may involve swelling of the tongue or throat, hoarseness, difficulty breathing or swallowing, dizziness, or fainting.

---

Q: Is Оксалиплатин intended as a cure, or to slow disease progression?

The medication is officially indicated for the treatment of advanced disease or as an adjuvant treatment, which is given after surgery to reduce the chance of the cancer returning. The supporting research for the drug tracks outcomes such as improved rates of disease-free survival and prolonged progression-free survival.

---

Q: What are the specific interactions with herbal supplements or vitamins?

Official regulatory interaction tables typically do not list specific herbal products or vitamins. However, because the drug works by causing cellular damage, there is a general concern that supplements with high antioxidant properties could potentially interfere with this process. This subject requires careful consideration regarding co-administration of supplements.

---

Q: Is it true that Оксалиплатин can affect heart function?

Yes, official safety information highlights a warning regarding the potential for this drug to cause a condition known as QT interval prolongation. This is an electrical disturbance that can affect the rhythm of the heart. For this reason, the use of the drug requires careful monitoring in patients with pre-existing heart conditions or electrolyte imbalances.

---

Q: Can Оксалиплатин be given if a person has pre-existing liver disease?

Оксалиплатин is not primarily broken down by the liver, but official safety information notes that one of the very common side effects is the elevation of liver enzymes. Therefore, patients with pre-existing liver issues are generally eligible for treatment but require close monitoring throughout their course of therapy.

---

Q: What is the risk classification for pregnant women exposed to Оксалиплатин?

The drug is formally listed as contraindicated for use during pregnancy, as it may cause harm to the fetus. The risk is high enough that in regulatory systems like Australia's TGA, it is classified under Pregnancy Category D, meaning there is evidence of fetal risk.

---

Q: Are there any restrictions on dental procedures during Оксалиплатин treatment?

Official documents emphasize the risk of myelosuppression, a very common side effect that causes low white blood cell and platelet counts. This effect creates a risk of infection and bleeding. For this reason, any planned dental procedures warrant discussion with the patient's healthcare team beforehand.

---

Q: What is the reason for the cold sensitivity experienced by some patients?

Studies investigating the drug’s effects on the nervous system provide insight into the cause of cold sensitivity. The drug is understood to temporarily alter the function of tiny structures within nerve cells called ion channels. This alteration makes the sensory nerves highly responsive and sensitive to cold temperatures.

---

Q: Are there different forms or brands of Оксалиплатин?

Оксалиплатин is the international nonproprietary (generic) name for the active ingredient. It is formulated as a concentrated solution or powder that is diluted for intravenous infusion. The U.S. brand name for this medicine is Eloxatin, and it may be available under other brand names internationally.

Storage and Disposal Requirements for Oxaliplatin

The Oxaliplatin concentrated solution must be stored at controlled room temperature (20 C to 25 C) and protected from light in its original outer carton. The concentrate must not be frozen.

Once diluted exclusively with 5% Dextrose Injection, USP, the solution is stable for 6 hours at room temperature or up to 24 hours under refrigeration (2 C to 8 C). Light protection is not required after final dilution.

Handling Context	Official Requirement
Child Safety	Keep out of the sight and reach of children.
Special Handling	Preparation and handling must be done by trained personnel due to its status as a cytotoxic agent.
Disposal	Unused product and waste must be discarded according to strict local and national regulations for hazardous/cytotoxic waste.